<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03707561</url>
  </required_header>
  <id_info>
    <org_study_id>NMIC for Cardiology</org_study_id>
    <nct_id>NCT03707561</nct_id>
  </id_info>
  <brief_title>RUS-registry of PH</brief_title>
  <official_title>Russian National Registry of Patients With Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Russian Cardiology Research and Production Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Scientific Research Institute of Rheumatology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Russian Cardiology Research and Production Center</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Russian National Registry of Patients With Pulmonary Arterial Hypertension (PAH) and Chronic
      Thromboembolic Pulmonary Hypertension (CTEPH) is a multicenter, observational study of the
      clinical course and disease management of PAH and CTEPH patients. designed to gather
      demographic, clinical and prognostic data of routine medical care in prospective manner for
      newly initiated treatment since Jan 2016.

      The internet-based registry (www.medibase.pro) fulfills high quality standards through
      several measures (planned minimum centre contribution of at least 10 patients per year,
      automated plausibility checks of data at entry, queries, monitoring with source data
      verification in &gt;50% of participating centers).

      All consecutive patients diagnosed with World Health Organization Pulmonary Hypertension
      Groups (WHO Group I) PAH according to specific hemodynamic criteria will be enrolled in
      participating centers after signing the informed consents. Participating patients will be
      followed for a minimum of five years from the time of enrollment.

      It can be applied, among further purposes, for quality assurance: individual centers can
      confidentially compare their results with the combined outcome of the other centers. It is
      expected that the registry contributes to optimization of specific drug therapy for PAH and
      Pulmonary Hypertension (PH).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Russian National Registry of Patients With Pulmonary Arterial Hypertension and Chronic
      Thromboembolic Pulmonary Hypertension (RUS-registry of PH) will report current and
      comprehensive data on

        -  Demographics, clinical course of incident PAH and CTEPH, the hemodynamic and functional
           status of patients

        -  The main diagnostic approaches for the diagnosis of PAH and CTEPH.

        -  Patient outcomes including survival, by subgroup, by treatment strategy and other
           factors

        -  Clinical predictors of short-term and long-term clinical outcomes

        -  Relationship between PAH- treatment medications and patient outcomes

        -  Temporal trends in treatments and outcomes for newly diagnosed patients

        -  The state of implementation of current PAH guidelines

        -  To describe the status of operable or non-operable patients with PAH and CTEPH

        -  To identify the most important prognostic indicators in patients with PH.

        -  To study the basic principles of therapy of patients with PH.patients

        -  To evolve research needs of the PAH community
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date>January 2016</start_date>
  <completion_date type="Anticipated">January 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>5 Years</target_duration>
  <primary_outcome>
    <measure>RHC</measure>
    <time_frame>12 month</time_frame>
    <description>Change of pulmonary vascular resistance</description>
  </primary_outcome>
  <number_of_groups>7</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Pulmonary Hypertension</condition>
  <arm_group>
    <arm_group_label>Group 1 - IPAH and heritable PAH</arm_group_label>
    <description>Idiopathic pulmonary arterial hypertension (IPAH) and heritable PAH Diagnostic Test: Right Heart Catheterization (RHC)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2- PAH associated with CHD</arm_group_label>
    <description>Pulmonary arterial hypertension associated with congenital heart disease Diagnostic Test: Right Heart Catheterization (RHC)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3- PAH associated with CTD</arm_group_label>
    <description>Pulmonary Arterial Hypertension associated with Connective Tissue Diseases Diagnostic Test: Right Heart Catheterization (RHC)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4- portoPH</arm_group_label>
    <description>Portopulmonary hypertension</description>
  </arm_group>
  <arm_group>
    <arm_group_label>group 5- PAH-HIV</arm_group_label>
    <description>Pulmonary arterial hypertension associated with HIV infection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>group 6- operable CTEPH</arm_group_label>
    <description>Operable chronic thromboembolic pulmonary hypertension Diagnostic Test: Right Heart Catheterization (RHC)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>group 7- non-operable CTEPH</arm_group_label>
    <description>Non operable chronic thromboembolic pulmonary hypertension Diagnostic Test: Right Heart Catheterization (RHC)</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Right Heart Catheterization (RHC)</intervention_name>
    <description>RHC at the enrollment and every 12 months</description>
    <arm_group_label>Group 1 - IPAH and heritable PAH</arm_group_label>
    <arm_group_label>Group 2- PAH associated with CHD</arm_group_label>
    <arm_group_label>Group 3- PAH associated with CTD</arm_group_label>
    <arm_group_label>group 6- operable CTEPH</arm_group_label>
    <arm_group_label>group 7- non-operable CTEPH</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        IPAH and heritable PAH, PAH associated with CHD, PAH associated with CTD, portoPH, PAH-HIV,
        operable CTEPH, non-operable CTEPH
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Newly diagnosed PAH:

        idiopathic form (IPAH) or PAH associated with connective tissue diseases (PAH-CTD), with
        congenital heart defects (PAH-CHD), with HIV infection (PAH-HIV), or portopulmonary
        hypertension Newly diagnosed CTEPH- operable and non-operable

        Documentation of the following hemodynamic parameters by right heart catheterization,
        performed at the time of study enrollment:

        Mean pulmonary arterial pressure (mPAP) ≥ 25 mm Hg at rest Pulmonary wedge pressure &lt; 15 mm
        Hg Pulmonary vascular resistance (PVR) ≥ 240 dynes.sec.cm-5 (i.e., ≥ 3.0 Wood units) Signed
        informed consent Previously naïve patients with newly initiated therapy with endothelin
        receptor antagonists (ERA), phoshodiesterase-5 (PDE-5) inhibitors, soluble guanylate
        cyclase (sGC) stimulators or prostacyclins in mono- or combination therapy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tamila Martynyuk, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Russian Cardiology Research and Production Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Irina Chazova, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Russian Cardiology Research and Production Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Olga Arkhipova, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Russian Cardiology Research and Production Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alexander Volkov, MD, PhD.</last_name>
    <role>Study Director</role>
    <affiliation>Institute of Rheumatology named after VA Nasonova, Moscow, Russia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Vera Lukyantchikova, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Regional Clinical Hospital №1, Khabarovsk, Russia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Elena Vetrova, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Belgorod Regional Clinical Hospital, Belgorod, Russia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Elena Devitiyarova, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Rostov Regional State CLINICAL HOSPITAL, Russia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Olga Korolkova, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Department of Hospital Therapy of the Voronezh State Medical Academy. N. N. Burdenko, Voronezh, Russia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Olga Andreyeva</last_name>
    <role>Study Director</role>
    <affiliation>State Healthcare Institution Regional Cardiology Dispensary, Ulyanovsk, Russia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Svetlana Martynenko</last_name>
    <role>Study Director</role>
    <affiliation>Regional Budget Cardiology Dispensary, Astrakhan, Russia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Elena Milovanova, PhD</last_name>
    <role>Study Director</role>
    <affiliation>District Cardiology Dispensary &quot;Center for Diagnostic and Cardiovascular Surgery&quot;, Surgut, Russia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Anna Rogacheva</last_name>
    <role>Study Director</role>
    <affiliation>State Future Health Care Institution &quot;Primorskaya Regional Clinical Hospital № 1&quot;, Vladivostok, Russia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Svetlana Kharitonova</last_name>
    <role>Study Director</role>
    <affiliation>State budgetary health care institution &quot;Bryansk Regional Cardiology Dispensary&quot;, Bryansk, Russia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Elena Shutemova, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>IVANOVO STATE MEDICAL ACADEMY Department of Therapy and General Practice, Ivanovo, Russia</affiliation>
  </overall_official>
  <link>
    <url>https://doi.org/10.1097/01.hjh.0000467958.52984.9f</url>
    <description>First date of Russian national registry of pulmonary arterial hypertension</description>
  </link>
  <link>
    <url>https://elibrary.ru/item.asp?id=29431631</url>
    <description>Comparative assessment of the demographic characteristics and functional ability of patients with PAH in the Russian registry and the largest foreign registers.</description>
  </link>
  <link>
    <url>https://elibrary.ru/item.asp?id=29431631</url>
    <description>Hemodynamic and functional characteristics of patients with different forms of pulmonary arterial hypertension according to the russian registration of patients with pulmonary hypertension.</description>
  </link>
  <link>
    <url>https://elibrary.ru/item.asp?id=27378932</url>
    <description>First results of a clinical analysis of patients with chronic thromboembolic pulmonary hypertension depending on their operability status according to the data of the Russian pulmonary hypertension register.</description>
  </link>
  <link>
    <url>https://elibrary.ru/item.asp?id=22674921</url>
    <description>Features of pulmonary arterial hypertension according to the Russian Register.</description>
  </link>
  <reference>
    <citation>Chazova IE, Martynyuk TV. [Clinical guidelines for the diagnosis and treatment of chronic thromboembolic pulmonary hypertension (Part 1)]. Ter Arkh. 2016;88(9):90-101. doi: 10.17116/terarkh201688990-101. Russian.</citation>
    <PMID>27735920</PMID>
  </reference>
  <reference>
    <citation>Chazova IE, Martynyuk TV. [Clinical guidelines for the diagnosis and treatment of chronic thromboembolic pulmonary hypertension (Part 2)]. Ter Arkh. 2016;88(10):63-73. doi: 10.17116/terarkh201688663-73. Russian.</citation>
    <PMID>27801422</PMID>
  </reference>
  <reference>
    <citation>Chazova IE, Avdeev SN, Tsareva NA, Volkov AV, Martyniuk TV, Nakonechnikov SN. [Clinical guidelines for the diagnosis and treatment of pulmonary hypertension]. Ter Arkh. 2014;86(9):4-23. Russian.</citation>
    <PMID>25518501</PMID>
  </reference>
  <results_reference>
    <citation>Taran IN, Belevskaya AA, Saidova MA, Martynyuk TV, Chazova IE. Initial Riociguat Monotherapy and Transition from Sildenafil to Riociguat in Patients with Idiopathic Pulmonary Arterial Hypertension: Influence on Right Heart Remodeling and Right Ventricular-Pulmonary Arterial Coupling. Lung. 2018 Dec;196(6):745-753. doi: 10.1007/s00408-018-0160-4. Epub 2018 Sep 4.</citation>
    <PMID>30182153</PMID>
  </results_reference>
  <results_reference>
    <citation>Chazova IE, Arkhipova OA, Valieva ZS, Nakonechnikov SN, Martyniuk TV. [Pulmonary hypertension in Russia: the first results of the national register]. Ter Arkh. 2014;86(9):56-64. Russian.</citation>
    <PMID>25518507</PMID>
  </results_reference>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>October 11, 2018</study_first_submitted>
  <study_first_submitted_qc>October 11, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 16, 2018</study_first_posted>
  <last_update_submitted>October 23, 2018</last_update_submitted>
  <last_update_submitted_qc>October 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 25, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Russian Cardiology Research and Production Center</investigator_affiliation>
    <investigator_full_name>Tamila V. Martynyuk, MD, PhD</investigator_full_name>
    <investigator_title>Russian Cardiology Research and Production Center</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension, Pulmonary</mesh_term>
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

